Compare · BRNS vs NVO
BRNS vs NVO
Side-by-side comparison of Barinthus Biotherapeutics plc (BRNS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRNS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.34B, about 6823.8x BRNS ($28.6M).
- Over the past year, BRNS is down 32.6% and NVO is down 39.9% - BRNS leads by 7.3 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 1 for BRNS).
- NVO has more recent analyst coverage (25 ratings vs 0 for BRNS).
- Company
- Barinthus Biotherapeutics plc
- Novo Nordisk A/S
- Price
- $0.68-2.76%
- $43.63-0.26%
- Market cap
- $28.6M
- $195.34B
- 1M return
- +7.28%
- -4.57%
- 1Y return
- -32.60%
- -39.85%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 1
- 11
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BRNS
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 3 filed by new insider Swirsky Douglas J
- SEC Form 10-Q filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
- SEC Form DEFM14A filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Leadership Update
- SEC Form 10-K filed by Barinthus Biotherapeutics plc
- Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates